BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Harmony Biosciences Stock Plummets on Failed Phase 3 Study
Harmony Biosciences Stock Plummets on Failed Phase 3 Study
5
3
BTCCSquare news:
Harmony Biosciences (HRMY) shares tumbled sharply after the company's Phase 3 trial for ZYN002 in Fragile X syndrome missed its primary endpoint. The drug candidate failed to demonstrate significant improvement in social avoidance, attributed to an unexpectedly high placebo response rate.
CEO Jeffrey M. Dayno maintained Optimism about the company's pipeline, highlighting upcoming Phase 3 trials for pitolisant HD in sleep disorders. The clinical setback underscores the high-risk nature of biopharma investments, where single trial outcomes can dramatically impact valuations.
By:
